AstraZeneca, Drug Prices & Medicare Spending

AstraZeneca manufactures 21 drugs tracked by Medicare Part D with total spending of $17.6B.

Drugs Tracked

$17.6B

Medicare Spending

$115.16

Avg Cost/Claim

86%

Have Generics

AstraZeneca Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Farxiga	Dapagliflozin	$266.00	$3.0B	+31.5%	Yes
2	Calquence	Acalabrutinib	$10,105.00	$2.9B	+34.2%	Yes
3	Tagrisso	Osimertinib	$11,591.00	$2.2B	+14.5%	No
4	Symbicort	Budesonide/Formoterol	$222.00	$1.9B	-6.4%	Yes
5	Lynparza	Olaparib	$10,588.00	$1.6B	+18.7%	Yes
6	Fasenra	Benralizumab	$2,836.00	$987.0M	+18.6%	No
7	Imfinzi	Durvalumab	$12,882.00	$876.0M	+24.6%	Yes
8	Breztri Aerosphere	Budesonide/Glycopyrrolate/Formoterol	$305.00	$756.0M	+48.3%	No
9	Crestor	Rosuvastatin	$28.00	$698.0M	-48.2%	Yes
10	Brilinta	Ticagrelor	$229.00	$567.0M	-8.4%	Yes
11	Seroquel	Quetiapine	$40.00	$345.0M	-38.4%	Yes
12	Onglyza	Saxagliptin	$126.00	$234.0M	-18.4%	Yes
13	Rosuvastatin	Rosuvastatin Calcium	$9.00	$234.0M	-14.6%	Yes
14	Nexium	Esomeprazole Magnesium	$48.00	$234.0M	-32.4%	Yes
15	Quetiapine	Quetiapine Fumarate	$27.00	$234.0M	-22.6%	Yes
16	Dapagliflozin	Dapagliflozin	$48.00	$234.0M	+18.4%	Yes
17	Metoprolol	Metoprolol Succinate	$6.00	$178.0M	-28.4%	Yes
18	Saphnelo	Anifrolumab	$5,563.00	$178.0M	+68.4%	Yes
19	Omeprazole	Omeprazole	$7.00	$123.0M	-24.6%	Yes
20	Kombiglyze	Saxagliptin/Metformin	$197.00	$123.0M	-18.4%	Yes
21	Byetta	Exenatide	$359.00	$89.0M	-28.6%	Yes

Frequently Asked Questions

AstraZeneca manufactures 21 drugs tracked by Medicare Part D, with total annual spending of $17.6B.

Imfinzi (Durvalumab) is the most expensive at $12,882.00 per claim.

18 of 21 AstraZeneca drugs (86%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

For this entity, the underlying data on this page comes from CMS Medicare Part D Drug Spending data. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.

Source: CMS Medicare Part D Spending, 2026.